StockSelector.com
  Research, Select, & Monitor Sunday, May 26, 2019 7:15:15 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Stemline Therapeutics, Inc.$14.97$.332.25%

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Stemline Therapeutics, Inc. has an overall rank of 6788 out of 6809 stocks based on 7 positive rankings and 13 negative rankings.

Positive Rankings
Estimated Revenue Growth
Stemline Therapeutics rank is 4
Historic Revenue Growth
Stemline Therapeutics rank is 195
PEGValue
Stemline Therapeutics has a PEG Value of $33.79. A stock is commonly considered to be fairly valued when its PE ratio equals its earnings growth rate. The PEG Value is the price where the PE Ratio, based on next year's earnings estimate, divided by the estimated growth rate over the next couple of years equals 1. This implies that if the company maintains its estimated growth rate, that the stock should gain 125.74% in the next year. Among companies with a PEG Value above the current stock price, Stemline Therapeutics is ranked 256.
90 Day Gain
Stemline Therapeutics rank is 264
Target Prices
The average analysts' target price is $18.00 for Stemline Therapeutics using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Stemline Therapeutics is ranked 722.
SSValue
The StockSelector Value for Stemline Therapeutics is $19.72. The StockSelector Value assumes the market consistently prices a stock around a given PE ratio and, therefore, multiplies the average PE (using forward earnings estimates) over the past three years by future earnings estimates. Among companies with a StockSelector Value above the current stock price, Stemline Therapeutics is ranked 1056.
Debt-to-Equity
Stemline Therapeutics rank is 1070
Negative Rankings
Price-to-Sales
Stemline Therapeutics rank is 24
Negative Net Margin
Stemline Therapeutics rank is 25
Down Ratings Revision
During the past month, the average analyst's rating or recommendation has decreased. Among companies that have been downgraded within the past month, Stemline Therapeutics is ranked 117.
Negative ROE
Stemline Therapeutics rank is 177
Negative ROA
Stemline Therapeutics rank is 181
Negative Cash Growth
Stemline Therapeutics rank is 215
Price-to-Book
Stemline Therapeutics rank is 337
High vPut/Call
Stemline Therapeutics has a high Put/Call ratio of 3.13 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Stemline Therapeutics is ranked 427.
High Put/Call
Stemline Therapeutics has a high Put/Call ratio of 1.55 on all open interest of options expiring in the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Stemline Therapeutics is ranked 445.
High/Dropping MACD
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Stemline Therapeutics is ranked 474.
Down EPS Surprise
Stemline Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.
Down EPS Surprise
Stemline Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.
10 Day Loss
Stemline Therapeutics rank is 1202







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.